MedeliX
Start asking

Ceftriaxone

Ceftriaxon Aptapharma, Ceftriaxon Ashcure, Ceftriaxon Bradex, Ceftriaxon Hameln · ATC code J01DD04

Also known as: Ceftriaxon, Seftriakson, Ceftriaxona · Brand names: Ceftriaxon Cnp, Ceftriaxon Dali Pharma, Ceftriaxon Hameln, Ceftriaxon Hexal, Ceftriaxon Hikma, Ceftriaxon Kabi, Ceftriaxon Kalceks, Ceftriaxon Puren, Ceftriaxon Qilu, Rocephine I.V., Ceftriaxon Aptapharma, Ceftriaxon Ashcure, Ceftriaxon Bradex, Ceftriaxon Mip, Ceftriaxon Sandoz …

Key facts
Active substance
Ceftriaxone
Drug class
Cephalosporin antibiotic
ATC code
J01DD04
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-11-03

Key facts

Ceftriaxone is a parenteral third-generation cephalosporin antibiotic given intravenously or intramuscularly. Per the US label it is used for a broad range of infections caused by susceptible bacteria, including meningitis, and for surgical prophylaxis.

What it is used for

  • Lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections
  • Complicated and uncomplicated urinary tract infections; uncomplicated gonorrhoea; pelvic inflammatory disease (add antichlamydial cover)
  • Bacterial septicaemia, bone and joint infections, intra-abdominal infections, meningitis
  • Surgical prophylaxis (single 1 g dose before contaminated or high-risk procedures)

Dosing

  • Adults: 1 to 2 grams once daily (or in two divided doses) depending on infection; maximum 4 grams per day
  • Uncomplicated gonorrhoea: a single IM dose in this older US label, lower than current STI guidelines recommend; surgical prophylaxis: single 1 gram IV dose before surgery
  • Children: 50 to 75 mg/kg per day (maximum 2 grams); meningitis 100 mg/kg/day (maximum 4 grams) for 7 to 14 days; otitis media single 50 mg/kg IM (maximum 1 gram)
  • Usual duration 4 to 14 days; continue at least 2 days after symptoms resolve; Streptococcus pyogenes at least 10 days
  • IV infusion over 30 minutes (60 minutes in neonates); no adjustment in renal or hepatic impairment alone, but not more than 2 g daily when both are significantly impaired

Contraindications

  • Hypersensitivity to ceftriaxone, any excipient or any other cephalosporin
  • Premature neonates up to a post-menstrual age of 41 weeks; hyperbilirubinaemic neonates (risk of bilirubin encephalopathy)
  • Neonates (≤ 28 days) requiring calcium-containing IV solutions (fatal ceftriaxone-calcium precipitates)
  • Intravenous use of ceftriaxone solutions containing lidocaine

Important warnings

  • Serious, occasionally fatal hypersensitivity (anaphylaxis); caution with penicillin or beta-lactam allergy
  • Never mix with or give simultaneously with calcium-containing IV solutions (e.g. Ringer’s); in non-neonates, sequential use only with thorough line flushing
  • Neurological reactions (encephalopathy, seizures, myoclonus, non-convulsive status epilepticus), especially in severe renal impairment
  • Clostridioides difficile-associated diarrhoea; immune haemolytic anaemia, including fatal cases
  • Gallbladder pseudolithiasis, urolithiasis and post-renal acute renal failure (mainly children; ensure hydration); pancreatitis; prothrombin time changes

Side effects

  • Eosinophilia (6%), thrombocytosis (5.1%), leukopenia (2.1%)
  • Diarrhoea/loose stools (2.7%), raised AST (3.1%) or ALT (3.3%), rash (1.7%)
  • Local reactions: pain, induration and tenderness (1%), phlebitis after IV use
  • Rare/postmarketing: anaphylaxis, haemolytic anaemia, agranulocytosis, SJS/TEN, pancreatitis, biliary sludge, kernicterus

Interactions

  • Calcium-containing IV solutions: precipitation; contraindicated in neonates
  • Vitamin K antagonists: increased bleeding risk; monitor coagulation and adjust anticoagulant
  • Incompatible in admixture with vancomycin, amsacrine, aminoglycosides and fluconazole; give sequentially with line flushing
  • May cause a positive Coombs’ test, false-positive urine glucose (non-enzymatic) and falsely low readings on some blood glucose meters

Pregnancy and breastfeeding

  • No embryotoxicity or teratogenicity in animal studies; no adequate human studies, use only if clearly needed
  • Low concentrations are excreted in human milk; use with caution when breastfeeding

Summary of the official product information, written with AI on 2026-11-03. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Germany

  • Ceftriaxon CnpCnp Pharma Gmbh · 2 register entries
  • Ceftriaxon Dali PharmaViatris Germany Gmbh · 1 register entry
  • Ceftriaxon HamelnHameln Pharma Gmbh · 1 register entry
  • Ceftriaxon HexalHexal Ag · 2 register entries
  • Ceftriaxon HikmaHikma Farmacêutica (Portugal), S.A. · 2 register entries
  • Ceftriaxon KabiFresenius Kabi Deutschland Gmbh · 2 register entries
  • Ceftriaxon KalceksKalceks · 1 register entry
  • Ceftriaxon PurenEugia Pharma (Malta) Limited · 1 register entry
  • Ceftriaxon QiluQilu Pharma Spain S.L. · 1 register entry
  • Rocephine I.V.Kohlpharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-03

Austria

  • Ceftriaxon AptapharmaApta Medica Internacional D.O.O. · 1 register entry
  • Ceftriaxon AshcureAshcure Pharma B.V. · 1 register entry
  • Ceftriaxon BradexBradex S.A. · 1 register entry
  • Ceftriaxon HamelnHameln Pharma Gmbh · 1 register entry
  • Ceftriaxon KabiFresenius Kabi Austria Gmbh · 2 register entries
  • Ceftriaxon KalceksKalceks · 1 register entry
  • Ceftriaxon MipMip Pharma Austria Gmbh · 1 register entry
  • Ceftriaxon SandozSandoz Gmbh · 2 register entries
  • Ceftriaxon SwyssiSwyssi Ag · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-03

Turkey

  • AdsefonADVANCE İLAÇ A.Ş. · 2 register entries
  • ArmaseftDRPHARMA İLAÇ SANAYİ VE DIŞ TİC. A.Ş. · 1 register entry
  • AvisefAVİS İLAÇ SAN. VE TİC. A.Ş. · 6 register entries
  • BulsefWORLD MEDICINE İLAÇLARI LTD. ŞTİ. · 8 register entries
  • CefadayBİOFARMA İLAÇ SAN. VE TİC. A.Ş. · 6 register entries
  • CefamedWORLD MEDICINE İLAÇLARI LTD. ŞTİ. · 2 register entries
  • CeforceİSTANBUL İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
  • CefridemPHARMADA İLAÇ SAN. VE TİC. A.Ş. · 6 register entries
  • CephaxonTOPRAK İLAÇ VE KİMYEVİ MADDELER SAN.VE TİC. A.Ş. · 4 register entries
  • DesefinDEVA HOLDİNG A.Ş. · 4 register entries
  • EqiceftTÜM-EKİP İLAÇ A.Ş. · 4 register entries
  • ForsefBİLİM İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
Show all 28 brand names
  • IesefMENARİNİ SAĞLIK VE İLAÇ SAN. TİC. A.Ş. · 4 register entries
  • MetcefWORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. · 5 register entries
  • NevaksonEİP ECZACIBAŞI İLAÇ PAZARLAMA A.Ş, GENSENTA İLAÇ SANAYİ VE TİC. A.Ş. · 3 register entries
  • NovosefAVİXA İLAÇ SAN. VE TİC. A.Ş. · 5 register entries
  • OnceftINCPHARMA İLAÇ SAN. VE TİC. LTD. ŞTİ. · 4 register entries
  • ReksonSANTASYA İLAÇ KOZMETİK MEDİKAL İTRİYAT PAZARLAMA SAĞLIK HİZMETLERİ VE İNŞAAT SAN. TİC. LTD. ŞTİ. · 3 register entries
  • RotacefWORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. · 3 register entries
  • SefabelNOBEL İLAÇ PAZARLAMA VE SAN. LTD. ŞTİ. · 2 register entries
  • SefbulDR. SERTUS İLAÇ SAN. VE TİC. LTD. ŞTİ. · 6 register entries
  • SefetkiTURK İLAÇ VE SERUM SAN. A.Ş. · 4 register entries
  • SeftrasimSM PHARMA İLAÇ SAN. LTD. ŞTİ. · 2 register entries
  • TeksefWORLD MEDICINE OPHTHALMICS İLAÇLARI LTD. ŞTİ. · 6 register entries
  • TregsPHARMAVİSİON SAN. VE TİC. A.Ş. · 4 register entries
  • TriaxonKOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. · 4 register entries
  • UnacefinYAVUZ İLAÇ ECZA DEPOSU MEDİKAL ÜRÜNLER SAN.VE TİC. A.Ş. · 6 register entries
  • VikisefTÜRKEM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-11-03

Brand names in 27 more European countries
Belgium
Ceftriaxon Hameln, Ceftriaxone Fresenius Kabi, Ceftriaxone Kalceks, Rocephine
Bulgaria
Медаксон, Цефамед, Цефтриаксон Mip, Цефтриаксон Аптафарма, Цефтриаксон Панфарма, Цефтриаксон Тенамид, Цефтриаксон Чайкафарма
Croatia
Ceftriakson Aptapharma, Ceftriakson Pontus, Ceftriakson Qilu, Ceftriakson Swyssi, Ceftriakson Vizpharm, Ceftriaxon Mip, Ceftriaxone Kabi, Lendacin, Longaceph, Medaxone
Cyprus
Ceftrix, Medaxonum
Czechia
Ceftriaxon Aptapharma, Ceftriaxon Kabi, Ceftriaxon Medochemie, Ceftriaxon Sandoz, Ceftriaxone Hameln, Ceftriaxone Kalceks, Ceftriaxone Noridem, Ceftriaxone Swyssi
Denmark
Ceftriaxon Fresenius Kabi, Ceftriaxon Hameln, Ceftriaxon Mip, Ceftriaxon Navamedic, Ceftriaxone Kalceks
Estonia
ceftriaxone Kabi, Ceftriaxone Mip, Medaxone
Finland
Ceftriaxon Fresenius Kabi, Ceftriaxon Hameln, Ceftriaxon Mip Pharma, Ceftriaxon Navamedic, Ceftriaxone Kalceks
France
Ceftriaxone Almus, Ceftriaxone Arrow, Ceftriaxone Biogaran, Ceftriaxone Cristers, Ceftriaxone Eg, Ceftriaxone Evolugen, Ceftriaxone Kalceks, Ceftriaxone Noridem, Ceftriaxone Panpharma, Ceftriaxone Qilu, Ceftriaxone Tamrisa, Ceftriaxone Teva Sante, Ceftriaxone Teva Santé, Ceftriaxone Viatris, Ceftriaxone Zentiva, Ceftriaxone Zydus, Rocephine, Triacefan
Greece
Bresec, Bresec(Iv), Ceftriaxone /Kabi, Ceftriaxone Norma, Ceftriaxone/Swyssi, Glorixone, Infeflox, Rolisporin, Travilan
Hungary
Ceftriaxon Aptapharma, Ceftriaxon Kabi, Ceftriaxon Noridem, Ceftriaxone Qilu, Ceftriaxone Swyssi
Iceland
Ceftriaxon Fresenius Kabi, Ceftriaxon Navamedic, Ceftriaxona Normon
Ireland
Ceftriaxone Hameln, Ceftriaxone Jed Pharma, Ceftriaxone Kalceks, Ceftriaxone Pinewood Laboratories, Rocephin
Italy
Bixon, Caritex, Cefrag, Ceftriaxone Accord, Ceftriaxone Almus, Ceftriaxone Aurobindo, Ceftriaxone Eg, Ceftriaxone Hameln, Ceftriaxone Kalceks, Ceftriaxone Mylan Generics, Ceftriaxone P-Care, Ceftriaxone Pensa, Ceftriaxone Qilu, Ceftriaxone Ratiopharm, Ceftriaxone Sandoz, Ceftriaxone Tecnigen, Ceftriaxone Zentiva, Davixon, Eraxitron, Nilson, Panatrix, Rocefin, Sirtap
Latvia
Ceftriaxon Mip, Ceftriaxone Ashcure, Ceftriaxone Bcpp, Ceftriaxone Kabi, Ceftriaxone Kalceks, Ceftriaxone Pharmsol, Ceftriaxone Unifarma, Ciplacef
Lithuania
Ceftriaxone Ashcure, Ceftriaxone Kabi, Ceftriaxone Mip, Ceftriaxone Pharmsol, Medaxone, Rezaxon
Luxembourg
Ceftriaxone Fresenius Kabi, Rocephine
Malta
Ceftriaxone Ashcure, Ceftriaxone Dali Pharma, Ceftriaxone Pharmsol, Ceftriaxone Pinewood Laboratories, Medaxonum
Netherlands
Ceftriaxon Fresenius Kabi, Ceftriaxon Hameln, Ceftriaxon Hikma, Ceftriaxon Kalceks, Ceftriaxon Navamedic, Ceftriaxon Sandoz
Norway
Ceftriaxon Fresenius Kabi, Ceftriaxon Hameln, Ceftriaxon Kalceks, Ceftriaxon Mip, Ceftriaxon Navamedic
Poland
Biotrakson, Ceftriaxon Aptapharma, Ceftriaxon-I.V. Mip, Ceftriaxon-I.V./I.M. Mip, Ceftriaxon Kabi, Ceftriaxone Kabi, Ceftriaxone Kalceks, Ceftriaxone Tzf, Tartriakson
Portugal
Betasporina, Ceftriaxona Asklepius, Ceftriaxona Bradex, Ceftriaxona Fresenius, Ceftriaxona Hikma, Ceftriaxona I.V. Generis, Ceftriaxona Kabi, Ceftriaxona Labesfal, Ceftriaxona Medlink Im, Ceftriaxona Omnicals, Ceftriaxona Reig Jofre, Ceftriaxona Sandoz, Ceftriaxone Medlink, Kemudin, Medaxone, Mesporin, Norvionix
Romania
Cefort, Ceftriaxonă Aptapharma, Ceftriaxonă Mip, Ceftriaxonă Swyssi, Medaxone, Seftrion
Slovakia
Ceftriaxon Kabi, Ceftriaxone Hameln, Ceftriaxone Kalceks, Ceftriaxón Aptapharma, Ceftriaxón Swyssi, Ceftron
Slovenia
Ceftriakson Aptapharma, Ceftriakson Pontus, Ceftriakson Qilu, Medaxone, Olicef
Spain
Ceftriaxona Fresenius Kabi, Ceftriaxona Ldp Torlan, Ceftriaxona Noridem, Ceftriaxona Normon, Ceftriaxona Qilu, Ceftriaxona Sala, Medaxone
Sweden
Ceftriaxon Fresenius Kabi, Ceftriaxon Hameln, Ceftriaxon Mip, Ceftriaxon Navamedic

EMA – Article 57 product data (EU/EEA), 2026-11-03

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Ceftriaxone Sodium (Hospira, Inc) – Prescribing Information, 2026-01-19. DailyMed (NLM), 2026-11-03. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03283208-8616-4117-9d2b-aa8046017a4f
  2. EMA – Article 57 product data (EU/EEA), 2026-11-03. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-11-03. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-11-03. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC J01DD.

Editorial: Medelix editorial team · last updated 2026-11-03 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.